60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $4.57M
• Dividend Yield: N/A
• Average Volume (3M): 3.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.57
• Revenue Growth: 168.70%
• EPS Growth: 31.57%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -27.07
• Shares Outstanding: 1,472,891
• 10 Day Avg. Volume: 8,987,810
• 30 Day Avg. Volume: 3,021,309
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 6.92
• Price to Cash Flow (P/CF): -0.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.40
• Price Target Upside: 14.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

SXTP is struggling with significant financial challenges, including declining revenues, persistent losses, and negative cash flow. Technical analysis suggests a bearish trend, and valuation metrics highlight the company's unprofitability. While there are some positive signs in equity improvements, the overall outlook remains concerning.

Positive Factors

Clinical Trial Success

A published clinical case series showed Arakoda displayed an 80% cure rate in patients with persistent, relapsing babesiosis who had failed previous treatments.

FDA Orphan Drug Designation

Arakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, enhancing its potential market value for a rare disease.

Sales Growth

Arakoda sales continue to grow, with net product revenues reaching $607,574, a significant increase from $253,573.

Negative Factors

Evaluation Challenges

The analyst maintains a Neutral rating due to difficulties in evaluating the company prior to receiving clinical data from the babesiosis program.

Market Insight

There is little insight into the malaria market, with findings from the pilot program awaited for more information.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company focused on the development and commercialization of treatments for tropical diseases and other global health concerns. Its core products include innovative therapeutics aimed at addressing malaria and dengue fever, diseases that significantly impact tropical regions across the globe.

How the Company Makes Money

60 Degrees Pharmaceuticals, Inc. generates revenue through the sale of its pharmaceutical products, primarily targeting tropical diseases. The company leverages strategic partnerships with global health organizations and governments to distribute its treatments in affected regions. Additionally, it may receive funding and grants to support research and development efforts aimed at expanding its product portfolio and enhancing the efficacy of its treatments. These collaborations and funding opportunities are crucial in driving the company's revenue and growth in the global health sector.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

60 Degrees Pharmaceuticals, Inc. is grappling with financial challenges, reflected in declining revenues, persistent losses, and negative cash flow. Recent improvements in equity and reduced debt are positive signs, but profitability and cash generation remain critical areas for improvement.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
449.79K	607.57K	253.57K	223.21K	1.16M	2.18M
	Gross Profit
36.85K	222.81K	-220.98K	-209.16K	309.60K	1.48M
	EBIT
-9.53M	-9.71M	-5.15M	-1.75M	-1.12M	-418.13K
	EBITDA
-7.87M	-9.71M	-1.43M	-2.11M	-1.01M	-341.17K
	Net Income Common Stockholders
-7.86M	-7.96M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
115.40K	3.39M	2.14M	264.87K	115.40K	191.70K
	Total Assets
1.39M	5.76M	7.78M	1.30M	1.39M	2.61M
	Total Debt
18.80M	0.00	172.67K	22.42M	18.80M	15.92M
	Net Debt
18.69M	-1.66M	-1.97M	22.15M	18.69M	15.73M
	Total Liabilities
19.55M	147.12K	2.99M	25.45M	19.55M	20.68M
	Stockholders Equity
-17.58M	3.96M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow		Free Cash Flow
-4.32M	0.00	-4.66M	-1.07M	-684.50K	-238.28K
	Operating Cash Flow
-4.07M	0.00	-4.54M	-1.01M	-649.11K	-167.30K
	Investing Cash Flow
-1.95M	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
	Financing Cash Flow
7.05M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.96
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Positive. The current price of 2.96 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 2.22, and below the 200-day MA of 5.98, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 35.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	83 Outperform	$422.91M	7.19	28.70%	10.13%	-0.86%	-13.33%
INVA	66 Neutral	$1.07B	83.75	3.42%	―	14.88%	-86.70%
BCRX	52 Neutral	$1.43B	―	18.68%	―	36.00%	63.50%
EBS	50 Neutral	$231.48M	―	-33.67%	―	-0.62%	75.57%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
SXTP	35 Underperform	$4.57M	―	-178.39%	―	168.70%	31.57%
NVAX	34 Underperform	$873.38M	―	30.06%	―	-30.65%	77.62%